那格列奈治疗2型糖尿病疗效及安全性研究

Clinical evaluation on efficacy and safety of nateglinide in the treatment of type 2 diabetes

目的 研究那格列奈对2型糖尿病的疗效及安全性.方法 选取2型糖尿病患者276例,按照随机数字表法分为那格列奈组138例,瑞格列奈组138例.分别给予那格列奈30 mg和瑞格列奈0.5 mg,每天3次,餐前15 min口服.12周为1个疗程.治疗前和治疗后检测空腹血糖（FBG）、餐后2h血糖（2 h PBG）、糖化血红蛋白（HbAlc）及安全性指标.结果 治疗后两组FBG、2 h PBG及HbAlc指标均较治疗前下降,差异有统计学意义（均P＜0.05）.组间比较,差异无统计学意义（均P＞0.05）,两组均未发生严重不良事件.结论 那格列奈能够有效控制2型糖尿病患者空腹及餐后血糖,安全可靠,值得临床推广.

Objective To evaluate the efficacy and safety of nateglinide, a new antidiabetic agent, in the treatment of type 2 diabetes. Methods 276 patients with type 2 diabetes mellitus,in accordance with the table of ran- dom number method, were divided into the nateglinide group 138 cases, repaglinide group 138 cases. The nateglinide group was given 30 mg nateglinide, and repaglinide group was given 0.5 mg repaglinide, 3 times a day, oral adminis- tration 15 min before meal. 12 weeks for one period of treatment. FBG, 2h PBG, HbAlc and security index were detec- ted before and after treatment. Results After treatment, FBG, 2h PBG and HbAlc indexes in the two groups were lower than before treatment, the differences were statistically significant（ all P 〈 0.05）. The differences were not sig- nificant compared between the two groups （ all P 〉 0. 05 ）. No serious adverse events occurred in two groups. Conclusion Nateglinide can effectively control fasting and postprandial blood sugar in patients with type 2 diabetes. It is safe and reliable and worthy clinical promotion.